NCT07833085Recruiting
CAIX-targeted PET/CT in Solid Tumors
Carbonic Anhydrase IX-targeted PET/CT Imaging for Detecting Solid Tumors
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 15 Sept 2026
- Start date
- 21 Sept 2026
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Zhongnan Hospital
- Diseases
- Kidney cancer, Lung cancer
- NCT number
- NCT07833085
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 21 Sept 2026 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants with severe liver and kidney dysfunction and cardiac dysfunction;
Other
- Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans;
- Pregnant or lactating women;
- Other situations that researchers believe should be excluded and documented.
Who the study is looking for
- Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology;
- Age of 18 years and above, both male and female are eligible;
- The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points;
- Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongnan Hospital of Wuhan University Coordinator of this site? Confirm its status | Wuhan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.